| Bioactivity | Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma[1][2]. |
| Target | IL-15 |
| In Vivo | Depemokimab (食蟹猴药代动力实验) 与 Mepolizumab (HY-P9945) 相比，清除率降低约 2 倍，IL-5 结合亲和力比 Mepolizumab 高约 30 倍[2]。 |
| Name | Depemokimab |
| CAS | 2243274-14-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Calzetta L, et al. Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. Biomedicines. 2022 Sep 19;10(9):2330. [2]. Singh D, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. |